Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection

NCT05594550 | Unknown

• 1 other identifier: NGUYEN 2022
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Sarcopenia is a risk factor for adverse outcome in critically ill patients. Sarcopenia might be estimated from muscle surface measure on tomodensitometry. The purpose of the study is to identify if muscle surfaces measured on thoracic tomodensitometry are associated with mortality in patients with acute respiratory distress syndrome due to SARS-Cov-2.

Conditions

Acute Respiratory Distress Syndrom (SARS-Cov 2)

Outcome Measures

Primary Outcomes (1)

• measurement of muscle area at T7 level indexed in cm²/m².

  use of CT measurements to discriminate between the 2 groups (deceased versus alive)

  At hospital admission

Secondary Outcomes (4)

• Duration of mechanical ventilation

  within the 28 days

• Ventilator free days

  within the 28 days

• number of days in Intensive care unit

  within the 28 days

• number of days in hospital

  within the 28 days

Study Arms (2)

28-day survival

Alive 28 days after intensive care admission

Other: Data collection; Other: analysis of thoracic scans

28-day death

Deceased 28 days after intensive care admission

Other: Data collection; Other: analysis of thoracic scans

Interventions

Data collection OTHER

Demographic data: Age, Sex, weight, height, main history and treatments. \- Biological data: CRP, PCT, albumin, pre-albumin

28-day death; 28-day survival

analysis of thoracic scans OTHER

muscle area calculated on the T7 and T12 thoracic slices

28-day death; 28-day survival

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adults with acute respiratory syndrome due to SARS-Cov-2

You may qualify if:

• patients hospitalized in intensive care for SARS-Cov-2 infection since january 2020
• Thoracic TDM within the 30 day preceding ICU admission and up to 24 hours after ICU admission

You may not qualify if:

• Pregnancy
• Neuromuscular disease

Sponsors & Collaborators

• Centre Hospitalier Universitaire Dijon: lead

MeSH Terms

Interventions

Data Collection

Intervention Hierarchy (Ancestors)

Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Central Study Contacts

Maxime NGUYEN

CONTACT

380293528; maxime.nguyen-soenen@chu-dijon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 21, 2022
• First Posted: October 26, 2022
• Study Start: October 1, 2022
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2022
• Last Updated: October 26, 2022

Record last verified: 2022-10